The short version of incretin fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-03. Anything still debated is marked as such rather than presented as settled.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Dissolution behavior depends on the amino acid sequence, the counterion content, and the buffer chosen. Many peptides disperse readily in water or mild aqueous buffers, while others require a small amount of organic co-solvent or a change in pH. Adsorption to plastic and glass surfaces can reduce the concentration of a solution over time, particularly at low concentrations. Filtration before analysis removes particulates, and aliquoting limits repeated freeze-thaw cycles that stress the material.
Research-grade peptide material is commonly supplied as a lyophilized powder, a form that limits degradation during transport and storage. Standard practice keeps such material cold and protected from light and moisture, with tighter conditions used for long-term archives. Once dissolved, solutions are generally considered less stable than the dry powder and are handled on shorter timescales. These established conventions derive largely from general peptide chemistry rather than from compound-specific evidence alone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.
Promethium (61Pm) is an artificial element, except in trace quantities as a product of spontaneous fission of 238U and 235U and alpha decay of 151Eu, and thus a standard atomic weight cannot be given. Like all artificial elements, it has no stable isotopes. It was first synthesized in 1945. Like technetium, it is preceded and followed by elements with stable isotopes. The known isotopes run from 128Pm to 166Pm, 39 in all; the most stable are 145Pm with a half-life of 17.7 years, 146Pm with a half-life of 5.53 years, and 147Pm (the common isotope) with a half-life of 2.6234 years. 143Pm and 144Pm also have lengthy if poorly-known lives on the order of a year, but all the others have half-lives that are less than six days, with the majority less than a few minutes. There are also 24 known meta states with the most stable being 148mPm at a half-life of 41.29 days. The primary decay mode for isotopes lighter than 146Pm is electron capture resulting in isotopes of neodymium, and the primary decay mode heavier than 146Pm is beta decay giving isotopes of samarium; promethium-146 itself decays both ways.
Insulin degludec/insulin aspart, sold under the brand name Ryzodeg, is a fixed-dose combination medication for the treatment of diabetes mellitus. It contains insulin degludec and insulin aspart. It is given as an injection under the skin in the abdominal wall (at the front of the waist), upper arm or thigh. The most frequently reported side effect is hypoglycemia (low blood glucose levels). It was approved for medical use in the European Union in January 2013, and in Australia in November 2017.
Standard reuptake inhibitors are believed to act simply as competitive substrates that work by binding directly to the plasmalemma transporter of the neurotransmitter in question. They occupy the transporter in place of the respective neurotransmitter and competitively block it from being transported from the nerve terminal or synapse into the pre-synaptic neuron. With high enough doses, occupation becomes as much as 80–90%. At this level of inhibition, the transporter will be considerably less efficient at removing excess d from the synapse and this causes a substantial increase in the extracellular concentrations of the neurotransmitter and therefore an increase in overall neurotransmission.
==== Gas scrubbing ==== Aqueous [Fe(EDTA)]− is used for removing ("scrubbing") hydrogen sulfide from gas streams. This conversion is achieved by oxidising the hydrogen sulfide to elemental sulfur, which is non-volatile:
Synthesis of vitamin D in nature is dependent on the presence of UV radiation and subsequent activation in the liver and the kidneys. Many animals synthesize vitamin D3 from 7-dehydrocholesterol, and many fungi synthesize vitamin D2 from ergosterol. Vitamin D3 is produced photochemically from 7-dehydrocholesterol in the skin of most vertebrate animals, including humans. The skin consists of two primary layers: the inner layer called the dermis, and the outer, thinner epidermis. Vitamin D is produced in the keratinocytes of the two innermost strata of the epidermis, the stratum basale and stratum spinosum, which also can produce calcitriol and express the vitamin D receptor. The 7-dehydrocholesterol reacts with UVB light at wavelengths of 290–315 nm. These wavelengths are present in sunlight, as well as in the light emitted by the UV lamps in tanning beds (which produce ultraviolet primarily in the UVA spectrum, but typically produce 4% to 10% of the total UV emissions as UVB). Exposure to light through windows is insufficient because glass almost completely blocks UVB light. In skin, either permanently in dark skin or temporarily due to tanning, melanin is located in the stratum basale, where it blocks UVB light and thus inhibits vitamin D synthesis. The transformation in the skin that converts 7-dehydrocholesterol to vitamin D3 occurs in two steps. First, 7-dehydrocholesterol is photolyzed by ultraviolet light in a 6-electron conrotatory ring-opening electrocyclic reaction; the product is previtamin D3.
Sources: en.wikipedia.org
Next to occupy the Oval Office, Reagan protégé and former VP George H. W. Bush (1989–93) maintained the hard line drawn by his predecessor and former boss. In his first prime time address to the nation, Bush held up a plastic bag of crack "seized a few days ago in a park across the street from the White House" (it was later revealed that DEA agents had to lure the seller to Lafayette Park to make the requested arrest). The administration increased narcotics regulation in the first National Drug Control Strategy, issued by the Office of National Drug Control Policy (ONDCP) in 1989. The director of ONDCP became commonly known as the US drug czar. In the National Defense Authorization Act for 1990–91, Congress included Section 1208 – the 1208 Program, expanded into the 1033 Program in 1996 – authorizing the Department of Defense to transfer surplus military equipment that the DoD determined to be "suitable for use in counter-drug activities", to local law enforcement agencies. As president, Bill Clinton (1993–2001), seeking to reposition the Democratic Party as tough on crime, dramatically raised the stakes for drug felonies with his signing of the Violent Crime Control and Law Enforcement Act of 1994. The act introduced the federal "three-strikes" provision that mandated life imprisonment for violent offenders with two prior convictions for violent crimes or drugs, and provided billions of dollars in funding for states to expand their prison systems and increase law enforcement.
=== Nanotechnology === Operando spectroscopy has become a vital tool for surface chemistry. Nanotechnology, used in materials science, involves active catalytic sites on a reagent surface with at least one dimension in the nano-scale of approximately 1–100 nm. As particle size decreases, surface area increases. This results in a more reactive catalytic surface. The reduced scale of these reactions affords several opportunities while presenting unique challenges; for example, due to the very small size of the crystals (sometimes <5 nm), any X-ray crystallography diffraction signal may be very weak. As catalysis is a surface process, one particular challenge in catalytic studies is resolving the typically weak spectroscopic signal of the catalytically active surface against that of the inactive bulk structure. Moving from the micro to the nano scale increases the surface to volume ratio of the particles, maximizing the signal of the surface relative to that of the bulk. Furthermore, as the scale of the reaction decreases towards nano scale, individual processes can be discerned that would otherwise be lost in the average signal of a bulk reaction composed of multiple coincident steps and species such as spectators, intermediates, and reactive sites.
=== Available forms === Selenium disulfide is available in the form of a prescription drug as a 2.25% medical shampoo. In the United States, a 1% strength is available over-the-counter, and a 2.5% strength is also available with a prescription. In Canada, the 2.5% strength is available over-the-counter. Selsun Blue is an over-the-counter shampoo for dandruff with 1% selenium disulfide as its active ingredient.
The discoverers also intended to reference the support of their research by the Japanese people (Riken being almost entirely government-funded), recover lost pride and trust in science among those who were affected by the Fukushima Daiichi nuclear disaster, and honour Japanese chemist Masataka Ogawa's 1908 discovery of rhenium, which he named "nipponium" with symbol Np after the other Japanese pronunciation of Japan's name. As Ogawa's claim had not been accepted, the name "nipponium" could not be reused for a new element, and its symbol Np had since been used for neptunium. In March 2016, Morita proposed the name "nihonium" to IUPAC, with the symbol Nh. The naming realised what had been a national dream in Japanese science ever since Ogawa's claim. The former president of IUPAP, Cecilia Jarlskog, complained at the Nobel Symposium on Superheavy Elements in Bäckaskog Castle, Sweden, in June 2016 about the lack of openness involved in the process of approving new elements, and stated that she believed that the JWP's work was flawed and should be redone by a new JWP. A survey of physicists determined that many felt that the Lund–GSI 2016 criticisms of the JWP report were well-founded, but it was also generally thought that the conclusions would hold up if the work was redone. Thus the new president, Bruce McKellar, ruled that the proposed names should be released in a joint IUPAP–IUPAC press release. IUPAC and IUPAP publicised the proposal of nihonium that June, and set a five-month term to collect comments, after which the name would be formally established at a conference.
Sources: en.wikipedia.org
Reduce particle size, for example by tempering chocolate Reduce particle density, by incorporating air pockets Increase the viscosity of the milk, by adding thickening agents Carrageenan is used at very low concentrations to form an imperceptible weak gel that prevents the large, dense particles of chocolate from sedimentation. Ready to drink chocolate milk should be refrigerated like unflavored milk, except some ultra-high temperature (UHT) pasteurized drinks, which can be stored at room temperature. However, it is generally served cold. The nutritional qualities of chocolate milk are the subject of debate: while some studies criticize the high sugar content of chocolate milk, other studies suggest that chocolate milk is nutritionally superior to white.
=== Ukraine === A people's deputy of Ukraine (Ukrainian: народний депутат України, narodnyi deputat Ukrayiny) is a member of parliament or legislator elected by a popular vote to the Verkhovna Rada (the unicameral parliament of Ukraine). Often people's deputies of Ukraine are referred to simply as deputies. The main statutes that define the order of elections, rights and duties of the people's deputies of Ukraine are outlined in Articles 76–81 of the Constitution of Ukraine. There are 450 people's deputies of Ukraine who are elected based on the general, equal and direct electoral right for five years. The deputies may be appointed to various parliamentary positions such as the chairperson (speaker) of parliament, a head of a committee or a parliamentary faction, etc. Upon its appointment, to the office, each people's deputy of Ukraine receives a deputy mandate. People's deputies that run for parliament as self-nominated candidates can join factions if they wish.
Xanthoria parietina serves as both a food source and shelter for certain gastropods. The snail Balea perversa uses the lichen for shelter and nourishment. Similarly, other gastropods, such as Helicigona lapicida, feed on Xanthoria parietina. This grazing may contribute to lichen dispersal: photobiont cells from X. parietina partially survive passage through the snail's digestive tract, retaining some photosynthetic activity even after digestion. Such survival raises the possibility that snail herbivory could facilitate lichen relichenization—either by recombining surviving symbionts from the same thallus or by mixing photobionts and mycobionts from different individuals in fecal deposits. However, digestion significantly reduces photobiont viability, with photobiont fluorescence (a measure of photosynthetic activity) declining by 41–44% after passage through the snail gut. While some cells remain intact, they often suffer morphological damage (including shrunken chloroplasts and enlarged cell wall-to-membrane distances), leaving it unclear whether surviving photobionts can effectively establish new lichens without viable fungal spores or hyphae.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
Mass spectrometry provides a mass value that can be compared with the expected value, while peptide mapping examines fragmentation patterns. Together these techniques support identity claims better than a single measurement can.